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Abstract: Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare inherited autosomal recessive disorder that presents with 
thrombocytopenia and absence of megakaryocytes. It presents with bleeding recognized on day 1 of life or at least within the first month. 
The cause for this disorder appears to be a mutation in the gene for the thrombopoeitin (TPO) receptor, c-Mpl, despite high   levels 
of serum TPO. Patients with severe Type I-CAMT carry nonsense Mpl mutations which causes a complete loss of the TPO receptor 
whereas those with Type II CAMT carry missense mutations in the Mpl gene affecting the extracellular domain of the TPO receptor. 
Differential diagnosis for severe CAMT includes thrombocytopenia with absent radii (TAR) and Wiskott-Aldrich syndrome (WAS). 
The primary treatment for CAMT is bone marrow transplantation. Bone Marrow/Stem Cell Transplant (HSCT) is the only thing that 
ultimately cures this genetic disease. Newer modalities are on the way, such as TPO-mimetics for binding towards partially functioning 
c-Mpl receptors and gene therapy. Prognosis of CAMT patients is poor, because all develop in childhood a tri-linear marrow aplasia 
that is always fatal when untreated. Thirty percent of patients with CAMT die due to bleeding complications and 20% -due to HSCT if 
it has been done.
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Background
Congenital  amegakaryocytic  thrombocytopenia 
(CAMT)  is  a  rare  autosomal  recessive  bone  mar-
row  failure  syndrome  that  presents  with  severe 
  thrombocytopenia  which  can  evolve  into  aplastic 
anemia and leukemia.1–3 The disorder is expressed 
in infancy with or without physical anomalies.4,5 It is 
often recognized on day 1 of life or at least within 
the first month. It is often initially confused with fetal 
and neonatal alloimmune thrombocytopenia, but the 
neonate fails to improve and responds only to plate-
let transfusion. Eventually, a diagnostic bone marrow 
is performed which can be technically difficult in a 
neonate.
A  recent  classification  was  proposed  in  2005 
  supported by several other reports based on the course 
on outcome of the disease as follows;1,5
a.  Type  I—early  onset  of  severe  pancytopenia, 
decreased  bone  marrow  activity  and  very  low 
platelet counts. In this group, there is complete 
loss of functional c-Mpl. Median platelet count is 
usually 21 × 109/L or below.5
b. Type  II—milder  form  with  transient  increases 
of  platelet  counts  up  to  nearly  normal  values 
  during the first year of life and an onset of bone 
  marrow failure at age 3 to 6 years or later. In this 
group, there are partially functional receptors for 
the c-Mpl gene. Median platelet count is usually 
35 × 109/L to 132 × 109/L.
c.  Type  III—there  is  ineffective  megakaryopoeisis 
with no defects in the c-Mpl gene.
presentation
The  primary  manifestations  are    thrombocytopenia 
and megakaryocytopenia or low numbers of   platelets 
and megakaryocytes. There is an absence of mega-
karyocytes in the bone marrow with no associated 
  physical  abnormalities.6  Platelet  size  is  usually 
normal.7    Bleeding  is  of  primary  concern:  cutane-
ous,  gastrointestinal,  pulmonary,  and  intracranial 
hemorrhage.5,7 However, the presence of a   normal 
number  of    megakaryocytes  on  an  initial  bone 
  marrow aspirate should not exclude CAMT from the 
  differential  diagnosis  of  thrombocytopenia  within 
the first year of life.3
Platelet  counts  among  neonates  are  usually  in 
the level of 150 × 109/L. In patients with neonatal 
  thrombocytopenia,  infants  may  show  a  pattern  of 
low/low-normal platelet counts (100–200 × 109/L), 
with  levels  falling  to  as  much  as  50–100  ×  109/L 
at  4–5  days  and  returns  to  normal  at  7–10  days. 
Late-onset    neonatal  thrombocytopenia  presents 
  usually after the first 3 days of life wherein platelet 
counts often drops rapidly to levels of 50 × 109/L or 
even more.8
The reasons why we have to suspect hereditary 
thrombocytopenia which includes;7,9
1. Familial history of thrombocytopenia, especially 
parent-child or maternal uncle-nephew.
2. Lack of platelet response to autoimmune thrombo-
cytopenia therapies.
3. Diagnostic  features  on  smear  such  as  abnormal 
size platelets, absence of platelet alpha granules, 
Dohle-like bodies or microcytosis.
4. Bleeding out of proportion to the platelet count.
5. Onset at birth.
6. Associated features such as absent radii, mental 
retardation, renal failure, high tone hearing loss, 
cataracts or the development of leukemia.
7. Persistence of a stable level of   thrombocytopenia 
for years. Some patients may present with pete-
chial  purpura,  cranial  hematoma  or  recurrent 
rectorrhagia.
pathophysiology
The  majority  of  patients  have  a  mutation  in  the 
gene for the thrombopoeitin (TPO) receptor, c-Mpl, 
resulting  in  high  levels  of  serum  TPO.1,10  TPO 
binding  stimulates  both  early  and  late  phases  of 
megakaryocytopoiesis, increasing the number, size, 
and  ploidy  of    megakaryocytes,  and  promoting  the 
expression  of  platelet-specific  markers.  TPO  also 
maintains the numbers of hematopoietic stem cells 
thus, any abnormalities contribute to the occurrence 
of both thrombocytopenia and pancytopenia in CAMT 
patients. In addition, there may be   abnormalities with 
the central nervous system including the   cerebrum 
and    cerebellum  which  could  cause  symptoms.10 
  Animals  deficient  for  TPO  or  c-Mpl  have  a  90% 
reduction  of  megakaryocytic  precursor  cells  and  a 
60%–80% decrease of both erythroid and myeloid 
progenitors.11
TPO, also known as c-Mpl ligand is a cytokine 
that  plays  a  central  role  in  megakaryopeoiesis  by Review of inherited thrombocytopenia
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  influencing the development and maturation of mega-
karyocytes and platelet production from   hematopoetic 
stem cells. TPO exerts its biological effects through 
the TPO receptor, c-Mpl. C-Mpl is a member of the 
cytokine  receptor  superfamily  and  its  function  is 
restricted to hematopoietic tissues and cells, such as 
bone marrow, spleen, fetal liver and CD34+ cells. 
Stimulation of c-mpl with TPO results in the acti-
vation  of  tyrosine  kinase  (Tyk2)  and  Janus  kinase 
(JAK2) family members, which in turn phosphorylate 
Stat5 and Stat3, causing their nuclear translocation 
and the   transcription of Stat responsive genes.12–18
Bone  marrow  failure  in  CAMT  is  congenital. 
The  pathophysiology  of  bone  marrow  failure  in 
CAMT  is  not  completely  understood.  It  has  been 
hypothesized  that  TPO  and  c-Mpl  are  necessary 
for the growth and maintenance of the hematopoi-
etic stem cell population.1,19, This has been shown 
both  in  vitro  and  in  vivo  with  murine  models. 
C-mpl  −/−  mice  have  demonstrated  a  deficiency 
in  megakaryocytes  with  severe  thrombocytopenia 
and high serum TPO levels similar to humans with 
CAMT.20 While widely thought to be a platelet disor-
der, amegakaryocytic thrombocytopenia frequently 
is  associated  with  the  development  of  aplastic 
  anemia. Of the   congenital bone marrow   failure syn-
dromes causing aplastic anemia, CAMT is the most 
likely to present in the neonatal period. Although the 
mechanisms leading to aplasia are unknown, the age 
of onset has been reported to depend on the sever-
ity of the c-MPL   functional defect. The percentage 
of  bone  marrow  cells    expressing  tumor  necrosis 
factor-a  and    interferon-g  increases  during  pancy-
topenia. As in other bone marrow failure diseases, 
these inhibitory cytokines contributed to the pancy-
topenia.19 A global reduction in hematopoietic pro-
genitor cells was also seen in these c-mpl   knockout 
mice.  Marrow    repopulation  studies  in  c-mpl  −/− 
mice have also shown decreased engraftment com-
pared to c-mpl + mice. These   studies indicate that 
c-mpl is necessary for hematopoietic progenitor cell 
development.21,22
Genetics
The myeloproliferative (Mpl) genes in patients with 
CAMT were analyzed and reported in some   literatures. 
The  defects  concern  the  incapacity  of  the TPO  to 
  fulfill its normal thrombopoeitic role as a result of 
the abnormalities in the c-Mpl gene that encodes the 
TPO  receptor.23–25  Two  heterozygous  mutations  of 
the c-Mpl gene: a gln 186-to-ter substitution in exon 
4 and a single nucleotide deletion in exon 10 were 
found in some patients with CAMT.10 Patients with 
severe Type I CAMT carries nonsense MPL mutations 
which causes a complete loss of the thrombopoeitin 
(TPO) receptor whereas those with Type II CAMT 
carries missense mutations in the Mpl gene affect-
ing the extracellular domain of the TPO   receptor.5 
Some  patients  have  inherited  two  different  muta-
tions of the c- Mpl gene resulting in   heterozygous 
states.12,26,27  However,  a  G304C  mutation  has  been 
suggested as seen more frequently in patients with 
CAMT.  They  described  a  homozygous  nonsense 
mutation  (C268T)  upstream  of  the  mutation  in 
the rare G304C polymorphism.1 There is a high rate 
of consanguinity between of parents of children with 
CAMT,  leading  to  the  inheritance  of  homozygous 
c-mpl mutations.28–30
A  genotype  to  phenotype  correlation  has  been 
made  with  the  type  of  mutation  corresponding  to 
the severity of disease. Patients with frameshift or 
  nonsense mutations had a rapid progression of bone 
marrow failure, whereas patients with heterozygous or 
homozygous missense mutations had milder   disease.1 
Perhaps,  this  is  related  to  residual  c-Mpl  protein 
function. The discovery of the c-mpl gene mutation 
as the cause for CAMT has lead to the development 
of diagnostic genetic testing and   prenatal diagnosis. 
The overall hematopoietic progenitor cells suggest 
that in the future, gene therapy may be a possible treat-
ment option for this disorder. It is   currently unknown 
what  effect  c-mpl  transduction  would  have  on 
c-mpl-deficient animal models. Retroviral-mediated 
gene transfer of c-mpl in normal mouse bone marrow 
cells has shown a reduction in megakaryopoiesis with 
enhanced erythropoiesis.25
Diagnosis and Testing
Diagnostic features include:
1. Defective signal and response to thrombopoeitin in 
megakaryocyte-colony formation—in the absence 
of a signal from thrombopoeitin, megakaryocytes 
do not proliferate.4
2. Decreased numbers of erythroid and myelocytic 
progenitors in clonal cultures.4Al-Qahtani
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3. Lack of Mpl mRNA in bone marrow monocellular 
cells.4
4. Elevated serum level of TPO.1,4
5. White blood cells and red blood cells gradually 
decrease with age.10
6. No  reactivity  to  TPO  by  the  hematopoietic 
  progenitor cells.1,10
7. Absent  surface  expression  of  the  TPO  receptor 
Mpl.10
8. Hypoplastic bone marrow without dysplasia.31
Mpl gene analysis is performed by bi-directional 
sequencing of the coding regions and splice sites 
of exons 1–12 of the Mpl gene. Mutations found 
in  the  first  person  of  a  family  to  be  tested  are 
confirmed  by  repeat  analysis  using  sequencing, 
restriction   fragment analysis, or other appropriate 
method. Using the GeneDx (GeneDx, DNA diag-
nostic experts, MD, USA) has 95%–97% sensitiv-
ity because it can detect almost all expected types 
of the Mpl gene, except for some promoter muta-
tions, large deletions or duplications that are out-
side the regions sequenced that can not be detected. 
Specimens usually are taken as a single sample with 
1.5  ml  whole  blood  in    ethylenediamineteraacetic 
acid (EDTA), buccal brushes as alternative samples 
or 10 mL of amniotic fluid.32 Cytogenic investiga-
tions and analysis can be done also by fluorescent 
in-situ hybridization (FISH) on interphase nuclei. 
Chromosome  analyses  are  performed  on  bone 
marrow and peripheral blood- simulated cultures. 
Skin  fibroblasts  can  be  cultured  and  quinacrine 
  fluorescence (QFQ) banding can be used for chro-
mosome analysis.33
Differential Diagnoses
Differential  diagnosis  for  severe  CAMT  includes 
thrombocytopenia with absent radii (TAR) and Wiskott-
Aldrich syndrome (WAS).24,34–36 These can be distin-
guished from CAMT on the basis of   associated skeletal 
hypoplasia of the arms (TAR) and   microthrombocytes 
(WAS).34,35 In addition,   antiplatelet antibodies maybe 
transferred from the mother to the child in-utero or at 
the time of delivery, causing severe thrombocytope-
nia. Women who lack common platelet antigens may 
produce antibodies against paternal antigens that are 
expressed in the developing fetus.
Treatment
Treatment options for CAMT are limited.   Supportive 
care  includes  judicious  use  of  unrelated  donor 
platelet  transfusions  (leucocyte-induced,  and 
  irradiated), avoidance of non-steroidal anti-inflam-
matory medications and aspirin, adjunctive therapies 
such  as  fibrinolytic  agents  for  minor  bleeding, 
and    monitoring  for  the  development  of  additional 
cytopenias.    Platelets  transfusions  may  be  efficient 
in increasing the   platelet count up to 10 days. Fre-
quent  platelet  transfusions  are  required  to  ensure 
that platelet levels do not fall to dangerous   levels, 
although this is not always the case.5 It is known for 
patients to continue to create very small numbers of 
platelets over time.   Desmopressin acetate (DDAVP) 
should be avoided in small infants due to the risk 
of hyponatremia but may be useful in older   children 
and adults. Cytokine   therapy with   interleukin-3 and 
granulocyte-macrophage    colony-stimulating  fac-
tor has been attempted but only resulted in   transient 
responses.1,36  Steroids  and  immunoglobulins  does 
not have an effect on thrombocytopenia, thus is not 
advised.5
The  primary  treatment  for  CAMT  is  bone 
  marrow transplantation.5,37 Bone Marrow/Stem Cell 
  Transplant is the only thing that ultimately cures this 
genetic disease. Children and their family members 
should be human leukocyte antigen (HLA)-typed to 
identify  possible  matched  related  donors.  Siblings 
that are heterozygous for a c-mpl mutation may have 
abnormal megakaryocytes despite normal peripheral 
platelet counts,12 and usually a sibling can be used as 
a donor.4 If a matched sibling is not available, trans-
plantation  may  still  be  necessary,  especially  when 
marrow failure ensues, but reported outcomes using 
matched unrelated donors have been poor and rates 
of graft failure are high.5,7 Newer modalities are on 
the way, such as TPO-mimetics for binding towards 
partially  functioning  c-Mpl  receptors38  and  gene 
therapy.39
prognosis and Mortality
Although  HSCT  has  been  implicated  to  treat 
  ultimately CAMT, preliminary studies showed that 
the prognosis of CAMT patients becomes poor when 
tri-linear  marrow  aplasia  develops  in  childhood.5 Review of inherited thrombocytopenia
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Furthermore,  a  single  study  showed  that  30%  of 
CAMT  patients  die  to  bleeding  complications  and 
20% is actually due to HSCT if it has been done.5 
Moreover, the same study showed that in patients who 
underwent HSCT, conditioning regimen with busulfan 
(BU)  and  cyclophosphamide  plus  antithymocyte 
globulin  and  graft-versus-host  prophylaxis  with 
cyclosporine and methotrexate improves survival up 
to 80% of patients.40
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